Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
I Can Extract Side Effects
Chapter 98

Three Purities Overseas Branch Established

1,654 words 6 min read 4 views 4mo ago Source ​
Skip to the end of the chapter
Prev
Next

Wei Kang, on the other hand, was in a great mood. This time, the AD Special Effect Drug was the only one of its kind in the world, and it had created such a huge buzz. He must have been out of his mind to license the drug to others.

As an adult, it's best to keep it firmly in your own hands.

Previously, Anti-cancer Drug was a very weak company, lacking both funds and manpower, and heavily in debt. It was just waiting for the rice to cook. At that time, of course Three Purities, it was necessary to cash out as soon as possible, obtain its first pot of gold, and get a return on investment as soon as possible.

There's no rush now. Three Purities is already a large pharmaceutical company with money, manpower, and various resources. Of course, it should take matters into its own hands, leverage its powerful momentum, and fully promote its overseas market.

Generally, entering any market requires application to the local drug regulatory authority, as different regions use different standards and regulations. Entering the Eagle Country market requires FDA approval, entering the China market requires CFDA approval, entering the Europa market requires CE certification, and entering the Bear Country market also requires medical registration.

This is where the FDA's authority comes into play. Once a drug FDA approval, it can open the door to most overseas countries. Although other countries also have their own drug review standards, they will generally refer to the FDA's clinical data and standards.

There are several strategies for domestic pharmaceutical companies to enter overseas pharmaceutical markets, especially the Eagle Country market.

The first type is licensing for joint development, commonly known as License Out.

Companies with high-value R&D products often choose to collaborate with local pharmaceutical companies to accelerate the R&D and approval of their products overseas. This collaboration model, which generates direct revenue through milestone payments, is the model chosen by most domestic pharmaceutical companies.

Because new drug development is often extremely risky and involves huge investments, many pharmaceutical companies cannot survive to the end. Therefore, they need to recoup their costs as soon as they achieve results, and licensing development is undoubtedly the best option.

The Anti-cancer Drug that Three Purities previously used followed this approach.

Other domestic pharmaceutical companies also have numerous classic examples in this regard.

For example, the global collaboration agreement signed between BeiGene and Merck Serono in 2013 to jointly develop the second-generation BRAF inhibitor BGB-283 provided BeiGene with a substantial amount of funding at a critical moment, and also saved BeiGene at a critical time.

The second option is to establish an overseas company for independent research and development.

Some pharmaceutical companies with strong overall capabilities often choose to submit their applications to the FDA themselves. If the drug is approved, the rights and interests belong to them. Currently, some large domestic pharmaceutical companies have clearly benefited from this and have been working hard in this area with considerable success.

Just like Hengrui Medicine, a leading domestic pharmaceutical company, which established a subsidiary in the Eagle Country, Hengrui Therapeutics, to engage in project acquisition and drug discovery activities. The company's initial pipeline of drugs included three oncology candidates spun off from Hengrui: Pyrrolutamide, SHR-A1201, and SHR1210 (a PD-1 monoclonal antibody).

In 2016, the company received a $100 million investment from Hengrui Medicine and an undisclosed blue-chip investment institution. Since 2017, three of the four innovative drugs approved for clinical trials by Hengrui Medicine in the Eagle Country were submitted by its subsidiary, Hengrui Therapeutics.

The third and final option is to apply for funding domestically.

These companies typically refer to generic drug manufacturers, and the products they apply for are generic drugs. Applying for generic drug approval is relatively simpler than for innovative drugs. Companies in this category usually do not choose to establish overseas subsidiaries, and generic drugs do not have licensing agreements. Therefore, most companies choose to apply to the FDA domestically or choose a suitable service agency in the Eagle Country to assist with the application process.

This is because the original drugs from overseas pharmaceutical companies are very expensive, so the FDA opens up clinical application and approval for generic drugs from other countries that are cheaper and of better quality, in order to reduce the burden on patients.

Just like the famous generic drugs from India, they are very popular in the Eagle Country, where they have already occupied 42% of the local generic drug market share.

Many domestic pharmaceutical companies are among them. For example, Dongying Pharmaceutical submitted an ANDA (Eagle Country New Drug Application) for a Blood-Sugar-Lowering Drug, Linagliptin, to the FDA last year and it was approved.

After developing a sound overseas expansion strategy and obtaining approvals from the FDA and other national drug regulatory agencies.

The subsequent commercial development of new drugs is also very important, mainly divided into two parts: promotion and sales.

Once a drug is approved by the FDA, those products that have been licensed for transfer and have overseas partners will develop the distribution market through their partners. However, for most pharmaceutical companies that did not have a partnership before approval, they choose to develop their own distributors and retail pharmacies.

Subsequent development involves two aspects, much like a person's two legs, neither of which can be missing. Both aspects need to work together to maximize the commercial potential of the drug.

One aspect is overall brand promotion.

As the saying goes, "an army marches on its stomach," and once a drug is approved, it needs the strong support of KOLs (Key Opinion Leaders) and public figures, both domestically and internationally.

In China, pharmaceutical companies often invite doctors to host or participate in product launch events to lay the foundation for future products.

Similarly, in the Eagle Country, promoting a drug's overall market is an essential part of a company's work, both before and after its approval.

In addition to educating the market and letting more doctors and patients know about the product's approval information, the extensive information exposure on social media also lays the groundwork for finding distributor partners later and increases bargaining power.

In terms of promotion focus, innovative drugs emphasize the advantages and value of the drugs, while generic drugs emphasize the cost-effectiveness of the drugs. Price wars have a natural advantage for China, a rising star.

On the other hand, it involves finding partners, including distributors, pharmacies, and hospitals.

Apart from the leading companies that have already obtained approval, most domestic pharmaceutical companies have a relatively weak foundation in this area and need to continuously accumulate experience.

Businesses can find partners on their own or choose to cooperate with professional service organizations to complement each other's strengths, and strive to establish cooperation with local distributors as soon as possible and achieve sales targets for their products.

The pharmaceutical sales market in overseas countries is very different from that in China. In China, most drugs are controlled by hospitals, and pharmacies only serve as a supplement to some over-the-counter drugs.

In countries like the Eagle Country, the main use of drugs in hospitals is concentrated in inpatient settings, while the retail sector, consisting of distributors and retail pharmacies, accounts for the majority of drug sales.

In 2018, the Eagle Country's healthcare expenditure reached 18.9% of its GDP, or $3.7 trillion, with prescription drug spending accounting for 12%. The entire prescription drug market was worth approximately $440 billion, with an average of 12 prescriptions issued per person per year and an average expenditure of $1,150 per person.

In the Eagle Country, when patients see a doctor, the doctor can only write a prescription and cannot sell the medicine in the hospital or his own clinic. However, patients can use the prescription to buy the medicine they need at any pharmacy, and the cost is shared between the patient and insurance (government health insurance + commercial insurance) according to a certain ratio.

The process is simple, but the underlying drug sales system is extremely complex, reflecting a complex chain of interests.

Pharmaceutical companies earn approximately 70% of the profits across the entire drug sales chain. Some analysts believe that the profits from patented drugs in the Eagle Country even exceed those of the tobacco industry.

Monopolistic practices, free pricing, and insurance coverage have made the Eagle Country the world's largest consumer of pharmaceuticals and the world's largest pharmaceutical market. Pharmaceutical companies from all over the world aspire to try their luck in the Eagle Country.

Shortly after, Three Purities issued another announcement on its official website, declaring the formal establishment of its Three Purities subsidiary.

"Sanqing Pharmaceutical's overseas subsidiary was recently officially established and is actively recruiting talents. We welcome capable, ambitious, and proactive individuals in the pharmaceutical industry to apply and join us in this great endeavor."

"The internationalization process of domestic pharmaceutical companies is like a mighty river flowing eastward, and we are moving forward with the tide. In the near future, Sanqing Pharmaceutical's overseas sales market will surely continue to break through and reach new heights, thus creating a truly world-class pharmaceutical company."

In addition to clinical trial application work, expanding overseas distributors and retail pharmacies and building a local sales team are the top priorities for Three Purities's overseas expansion this time.

At the same time, a wave of international talent recruitment was launched. Due to the renowned reputation of the new drug with effective treatment for Alzheimer's disease, many industry talents came to apply.

At the same time, various countries also announced the introduction of the Three Purities AD Special Effect Drug.

In terms of the approval process, we strive to expedite the process and initiate clinical trials as soon as possible to accelerate the market launch.

Patients and their families in Western countries were relieved to learn that the new drug was finally about to begin Phase III clinical trial.

Many people went to relevant hospitals and clinical research institutions to apply.

After all, they've been making such a fuss for so long, isn't it all to get involved in clinical trials as soon as possible?

Now, patients are eagerly awaiting this new drug to save their lives.

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Wei Kang
China
Eagle Country

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS